You can use the system without an Internet connection but your BGaze ACE needs a reliable internet connection for installing updates and generation of reports. We need some ports to be open - specifically ports 1433, 9010, 82, 433 and 22. These are normally open in most systems; however especially in larger clinics your IT department may have closed them.
You can check whether your port is open or not through this link https://portchecker.co/
We have a known issue with the AVG anti-virus software. If you have this antivirus installed in your computer, you need to add an exception that allows our software to connect with our online data interpretation server.
In other cases, you may need to temporarily disable the antivirus software. Please contact your regular IT support staff for details - it's not a complicated thing to do for people with some IT knowledge.
In Europe, several countries do not apply VAT to medical professions (e.g. in Spain). As a consequence clinics cannot recover VAT they pay in Spain.
As a general rule we need to charge VAT to any client in Europe, wherever the client is located. The only exception is that of a VAT susceptible intercommunitary registered business or freelancer based within the EU but outside Spain. To qualify, your VAT number needs to be registered in this database:
https://europa.eu/youreurope/business/taxation/vat/check-vat-number-vies/index_en.htm
If your VAT number is registered here, then our online shop will automatically apply a 0% VAT rate. You may still however need to pay this VAT in your own country - talk to your local tax advisor for details.
BGaze Clinic consists in an in-house developed biometric software platform designed to capture biomarker (Cognitive vergence) information through captivating video game experiences and a remote cloud server with Artificial Intelligence algorithms for data interpretation and patients’ classification.
BGaze Clinic semi-structured interview is taken from the well-known ACE and ACE+ ADHD diagnostic protocols published by Psychology Limited in the UK. These are semi-structured interviews authored by Dr Susan Young, a leading expert on ADHD diagnosis.
BGaze Clinic is EU certified as a class 1 medical device.
The neural marker is clinically validated (Valera P et al. 2018. Clinical Validation of Eye Vergence as an Objective Marker for Diagnosis of ADHD in Children. Journal of Attention Disorders Volume: 23 issue: 6, page(s): 599-614) together with leading hospitals (King’s College London, Vall d’Hebron University Hospital, Mataró Hospital, Sant Joan de Déu Hospital), universities (New York Syracuse University, Goethe University, Autonomous University of Barcelona, Polytechnic University of Catalonia) and research institutes (Biomedical Network Research Centre on Mental Health, ICREA) as an observer-independent marker for the diagnosis of the ADHD. Accuracy of the biomarker is 92.8% (false positive: 5.3%; false negative: 8.5%; area under the curve: 0.97).
The ACE and ACE+ protocols have been used in tens of thousands of clinical diagnostic processes in over 15 countries across the world.
The BGaze Clinic CPT include biomarker assessment. The neural marker is validated as an observer-independent marker for the diagnosis of ADHD and dyslexia. The biomarker assessment is given in likelihood from 0 (low) to 1 (high) of suffering ADHD and a severity level of ADHD from 0 (mild) to 1 (severe), and an ADHD profile (inattentive, combined, hyperactive).
Likelihood score of 0.66 (high) or higher support ADHD as main diagnosis. Scores lower that 0.33 (low) do not support ADHD diagnosis. To avoid confusions severity score is turned grey when the likelihood score falls within the first part of the bar (low; when the score is lower than 0.33). Because in this case the likelihood score does not support ADHD as diagnosis.
If a patient scores between 0.33 and 0.66 (medium) then the severity score can be helpful to reach a diagnosis. As a general rule, the higher the severity score the more it supports an ADHD diagnosis.
In the situation when the scores for likelihood and severity have both mid-level values (Moderate in the likelihood score and Medium in severity score) a more precise evaluation of the outcomes is required, and clinical evaluation must be taken into account to make final clinical diagnosis.
Besides, the report represents the CPT task statistics as such. These are known to have reasonable correlation with ADHD profiles on a population level, in particular reaction time variability (Tamm et al., 2012, Neurotherapeutics 9:500-508), but they have limited predictive value in individual cases classification.